Pathkey.AI Limited
AASX:PKY0.02
AUD
0.00
(0.00%)
Pathkey.AI Limited
ASX:PKY
(Australian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.- Similar Companies
- Business
- Pathkey.AI Ltd is a technology-driven biomedical data and insights company that develops digital instruments and analytics to accelerate clinical trials, enhance patient experience, and derive actionable market insights from social media and other real-world data sources. The company focuses on TrialKey, a data and AI-driven platform designed to support trial design, monitoring, and decision-making; it provides digital tools, data services, and insights across healthcare, wellness, and life sciences sectors; and it pursues adjacent revenue streams through research investments, partnerships, and joint ventures. Pathkey.AI operates primarily in Australia with operations and commercial engagements extending to global biopharma, contract research organizations (CROs), insurers, and health-tech clients, leveraging data partnerships and technology alliances to expand its reach. The business was founded in 2020 and is headquartered in Frankfurt am Main, Germany, with a corporate presence in Australia and other international markets. Subsidiaries and strategic affiliates support specialized capabilities in AI-driven clinical research, biotech investments, and insurance-linked services, reinforcing an integrated platform approach. The company emphasizes core offerings including AI-powered analytics for clinical trial optimization; patient experience enhancement tools and digital health solutions; social media and real-world data insights for market intelligence; risk assessment and insurance-related services tied to trial outcomes; and collaborative ventures in biotech and financial technology to diversify revenue and scale deployment. Key recent developments include partnerships and strategic alliances to accelerate global expansion of TrialKey and related services; new product launches and service offerings that broaden data-driven decision support for investigators, sponsors, and insurers; and capital-structure evolutions and strategic investments that strengthen liquidity and funding channels. Pathkey.AI positions its products and services to serve pharmaceutical developers, CROs, health networks, insurers, and research institutions seeking end-to-end AI-enabled clinical research support, real-world evidence generation, and market intelligence. The company highlights a multi-sided platform model that integrates software tools, data services, and advisory capabilities to deliver end-to-end value across discovery, development, and post-approval phases, supported by a global partner network and ongoing R&D investments. Pathkey.AI maintains a commitment to advancing AI-enabled drug discovery, trial optimization, and healthcare insights through continuous product improvement, geographic diversification, and collaborations with industry players to scale impact.